rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although an increasing number of studies report an association between the RNASEL G1385A variant and prostate cancer risk; this variant does not appear to be implicated in the development of breast cancer.
|
15330212 |
2004 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Prostate tissue specimens of 200 patients with prostate cancer were genotyped for R462Q by real time polymerase chain reaction allelic discrimination and were screened for XMRV proviral DNA by real time polymerase chain reaction specific for the envelope gene.
|
23098452 |
2012 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This prospective study suggests that prostate cancer in patients with the R462Q allelic variant of the HPC1/RNASEL gene is not associated with more aggressive clinical or pathological features in radical prostatectomy specimens.
|
18289577 |
2008 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We determined that the RNASEL variant Arg462Gln has three times less enzymatic activity than the wildtype and is significantly associated with prostate cancer risk (P = 0.007).
|
12415269 |
2002 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, the RNASEL Arg462Gln polymorphism may contribute to the risk of developing prostate cancer in African descendants and Hispanic Caucasians.
|
29088852 |
2017 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
There was an inverse association between RNASEL rs486907 and prostate cancer in younger men (<65 years) and those with a first-degree relative with prostate cancer; men with AA genotype had ORs of 0.64 and 0.47 (both P < 0.05), respectively, in comparison to men with GG genotype.
|
20564318 |
2010 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Overall, we found that both Asp541Glu and Arg462Gln polymorphisms were not associated with PCa risk (for Asp541Glu polymorphism: Glu/Glu vs. Asp/Asp: OR 1.17, 95% CI: 0.95-1.45, P = 0.13; Glu/Asp vs. Asp/Asp: OR 1.02, 95% CI: 0.92-1.14, P = 0.70; for Arg462Gln polymorphism: Gln/Gln vs. Arg/Arg: OR 0.98, 95% CI: 0.88-1.08, P = 0.62; Gln/Arg vs. Arg/Arg: OR 0.97, 95% CI: 0.91-1.04, P = 0.53).
|
21656378 |
2012 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we attempt to measure the prevalence of XMRV in prostate cancer cases in Germany and determine whether an analogous association with the R462Q polymorphism exists.
|
19835577 |
2009 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This suggests that among Caucasians, positive association between higher trans-fatty acid consumption and prostate cancer may be modified by the functional RNASEL variant R462Q.
|
17234723 |
2007 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A positive result for XMRV was not significantly correlated with the R462Q polymorphism (P = .82) or clinical pathological parameters of prostate cancer, including Gleason score (P = .29).
|
20936978 |
2010 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Meta-analyses revealed significant associations of prostate cancer with MSR1 IVS7delTTA, -14,742 A>G, and Arg293X in European Americans; Asp174Tyr in African Americans; RNASEL Arg462Gln in European American's overall and in family history-negative disease; and Glu265X in family history-positive European Americans.
|
15824169 |
2005 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutations or variants that impair function of RNase L, particularly R462Q, have been proposed as susceptibility factors for prostate cancer.
|
16609730 |
2006 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Studies revealing conflicting results on the role of RNASEL polymorphisms Glu265X, Arg462Gln, and Asp541Glu on prostate cancer risk led us to perform a meta-analysis to investigate the association of these polymorphisms and prostate cancer risk.
|
17020975 |
2006 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We did not detect an association between prostate cancer risk and the RNASEL R462Q variant.
|
18767027 |
2008 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using 1624 prostate cancer cases and 801 unaffected controls, the truncating mutation E265X and five common sequence variants, including the two missense mutations R462Q and D541E, were evaluated for association between genotypes/haplotypes and prostate cancer risk.
|
15534086 |
2004 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our study provides the proof-of-principle that some of the genetic variants (such as rs486907, rs627928 and rs2127565) in genes RNASEL, MSR1 and ELAC2 can be used as predictors of aggressiveness and progression of PCa.
|
26251261 |
2015 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Based on our search for manuscripts reporting prostate cancer susceptibility related to the rs486907 polymorphism, 16 case-control studies from 13 different publications were retrieved.
|
29317837 |
2018 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, RNase L(R462Q) was deficient in causing apoptosis in response to 2-5A consistent with its possible role in prostate cancer development.
|
14583476 |
2003 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To study the association between the polymorphisms Arg462Gln and Asp541Glu from the RNASEL gene (1q25), and the polymorphisms rs620861, rs1447295, rs6983267, rs7837328 from the chromosome 8q24 with the risk of presenting prostate cancer (PCa) and its clinical characteristics in a Hispanic (Chilean) population.
|
24224612 |
2014 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Xenotropic murine leukemia virus (MLV)-related virus (XMRV) was initially identified in prostate cancer (PCa) tissue, particularly in the prostatic stromal fibroblasts, of patients homozygous for the RNASEL R462Q mutation.
|
21447170 |
2011 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We found no evidence of association between R462Q and D541E polymorphisms and prostate cancer risk in our case/control analysis.
|
18189233 |
2008 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
CONCLUSIONS We report the effect of rs627928 on the development of prostate cancer and confirm that rs486907 is not involved in the risk of prostate cancer in the current meta-analysis.
|
31686670 |
2019 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
No statistically significant association was observed between the Arg462Gln polymorphism and prostate cancer (compared to Arg/Arg, Gln/Arg: OR= 0.99 95% CI 0.84-1.16; Gln/Gln: OR= 0.95 95% CI 0.74-1.21), although slight non-significant differences in risk were observed among men with the Gln/Gln genotype by stage and grade.
|
17407163 |
2007 |
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Arg462Gln sequence variation in the prostate-cancer-susceptibility gene RNASEL and age of onset of hereditary non-polyposis colorectal cancer: a case-control study.
|
16054567 |
2005 |